食管癌调强放疗的长期生存与毒性结局:大型单中心队列研究
该研究回顾性分析了587例非转移性食管癌患者接受调强放疗(IMRT)联合化疗的长期结局。中位随访31.4个月,中位总生存38.9个月,5年总生存率41.2%;≥3级肺炎和食管炎发生率分别为1.4%和13%。作者认为IMRT在光子放疗中疗效优异,应考虑用于食管癌治疗。
要点
- 587例非转移性食管癌患者接受IMRT联合同期化疗,中位放疗剂量50.4 Gy/28次。
- 中位总生存38.9个月,1年、3年、5年总生存率分别为86.7%、51.8%、41.2%。
- ≥3级肺炎发生率1.4%,≥3级食管炎发生率13%;手术患者术后常见并发症包括肺炎9.6%、吻合口漏11.1%、房颤12.5%。
核心结论
- 对于光子放疗,IMRT治疗食管癌可获得优异的长期生存结局,应考虑用于食管癌治疗。
- 这是迄今最大的单中心关于IMRT治疗食管癌长期结局的研究。
研究设计与样本
- 回顾性分析2004年1月至2013年6月连续接受IMRT治疗的587例非转移性食管癌患者。
- 所有患者为I-IVA期(AJCC 2002),接受术前或根治性同期化疗。
- 采用Kaplan-Meier法计算总生存、无局部区域复发生存和无病生存,不良事件按CTCAE 4.0分级。
主要发现
- 中位放疗剂量为50.4 Gy/28次,全组中位随访31.4个月(范围2.9-130.7个月),生存者中位随访61.8个月(范围7.7-130.7个月)。
- 中位总生存38.9个月,1年、3年、5年总生存率分别为86.7%、51.8%、41.2%。
- 1年、3年、5年无局部区域复发生存率分别为77.6%、68.2%、66.1%;无病生存率分别为58.6%、43.7%、41.4%。
- 8例(1.4%)发生≥3级肺炎,74例(13%)发生≥3级食管炎。
- 手术患者术后最常见并发症为肺炎(9.6%)、吻合口漏(11.1%)和房颤(12.5%)。
关键数值与推荐
- 中位放疗剂量50.4 Gy,分28次每日照射。
- ≥3级肺炎发生率1.4%,≥3级食管炎发生率13%。
- 手术患者术后肺炎9.6%、吻合口漏11.1%、房颤12.5%。
临床怎么用
- 对于非转移性食管癌,IMRT联合同期化疗可作为光子放疗下的治疗选择。
- 治疗中需关注≥3级食管炎(13%)和肺炎(1.4%)等毒性。
- 术后患者应警惕肺炎、吻合口漏和房颤等常见并发症。
局限性
- 回顾性单中心设计,可能存在选择偏倚。
- 随访时间有限,全组中位随访31.4个月。
- 未报告与历史对照或其他放疗技术的直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In patients with esophageal cancer (EC), intensity modulated radiation therapy (IMRT) improves dose sparing to the heart and lung, with some evidence showing clinical benefit. Herein, we report our cumulative clinical experience with the use of IMRT for EC. METHODS AND MATERIALS: This is a retrospective analysis of 587 patients with nonmetastatic EC who were treated consecutively with IMRT from January 2004 to June 30, 2013. All patients with stage I-IVA (American Joint Committee on Cancer 2002) received concurrent chemoradiation therapy either preoperatively or definitively. The Kaplan-Meier method was used to compute overall survival (OS) and locoregional recurrence-free survival and disease-free survival. The Common Terminology Criteria for Adverse Events, Version 4.0 were used to grade acute and subacute complications. RESULTS: The median radiation dose was 50.4 Gy in 28 daily fractions. As of July 2015, the median follow-up was 31.4 months (range, 2.9-130.7 months) for all patients and 61.8 months (range, 7.7-130.7 months) for survivors. The median OS was 38.9 months, and the 1-, 3-, and 5-year OS rates were 86.7%, 51.8%, and 41.2%, respectively. The 1-, 3-, and 5-year locoregional recurrence-free survival rates were 77.6%, 68.2%, and 66.1%, respectively, and the 1-, 3-, and 5-year disease-free survival rates were 58.6%, 43.7%, and 41.4%, respectively. Outcomes for both trimodality and bimodality treated patients were better than the outcomes reported in the literature. Eight patients (1.4%) experienced grade ≥3 pneumonitis, and 74 patients (13%) developed grade ≥3 esophagitis. For patients who underwent surgery, the most common postoperative complications were pneumonia (9.6%), anastomotic leakage (11.1%), and atrial fibrillation (12.5%). CONCLUSIONS: This is the largest, single institutional study to date on the long-term outcomes of treatment with IMRT for EC. For photon-based radiation therapy, IMRT yields excellent outcomes and should be considered for the treatment of EC.
引用
- Shi A, Liao Z, Allen PK, et al. Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. Adv Radiat Oncol. 2017. PMID: 29114598. doi:10.1016/j.adro.2017.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。